UCSB Arts & Lectures and the Cancer Foundation of Santa Barbara host the Nobel Prize–winning biochemist for a talk on CRISPR ...

Co-hosted by UC Santa Barbara Arts & Lectures and the Cancer Foundation of Santa Barbara, the talk will discuss CRISPR-Cas9 ...

Jennifer Doudna on the Brave New World Being Ushered In by Gene Editing The technology’s promise can sound like science fiction—it might help us adapt to a radically different climate ...

Jennifer Doudna on the Brave New World Being Ushered In by Gene Editing The technology’s promise can sound like science fiction—it might help us adapt to a radically different climate ...

The technology’s promise can sound like science fiction—it might help us adapt to a radically different climate, or grow organs for people in need—but experts are also concerned about its potential ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Hold rating on Editas Medicine (EDIT – Research Report), ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Editas Medicine (EDIT – Research Report). The ...

Oppenheimer analyst Jay Olson maintained a Hold rating on Editas Medicine (EDIT – Research Report) today and set a price target of ...

In a report released today, Liisa Bayko from Evercore ISI maintained a Hold rating on Editas Medicine (EDIT – Research Report), with a ...

JonesTrading analyst Debanjana Chatterjee has assigned their bullish stance on NTLA stock, giving a Buy rating on October 16. Debanjana ...

Analyst Yanan Zhu of Wells Fargo maintained a Buy rating on Editas Medicine (EDIT – Research Report), with a price target of $9.00. Yanan ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jack Allen ...